ABSTRACT Mice with genetic muscular dystrophy were treated with intraperitoneal injections of the proteinase inhibitor leupeptin, beginning before the onset of weakness. A significant number of the treated animals failed to develop histological evidence ofdystrophy, compared with controls. Leupeptin treatment prevented (or delayed) the onset of muscular dystrophy in this experiment. In muscular dystrophy, there is biochemical and morphological evidence of abnormality of the muscle cell plasma membrane (1-3). Such defective membranes may allow calcium influx, leading to activation of proteinases and initiating muscle fiber necrosis (4-6). The. eventual severe loss of sarcoplasmic and contractile proteins in dystrophy is associated with increased activity of acidic and neutral proteinases (7-10).
ABSTRACT Mice with genetic muscular dystrophy were treated with intraperitoneal injections of the proteinase inhibitor leupeptin, beginning before the onset of weakness. A significant number of the treated animals failed to develop histological evidence ofdystrophy, compared with controls. Leupeptin treatment prevented (or delayed) the onset of muscular dystrophy in this experiment. In muscular dystrophy, there is biochemical and morphological evidence of abnormality of the muscle cell plasma membrane (1) (2) (3) . Such defective membranes may allow calcium influx, leading to activation of proteinases and initiating muscle fiber necrosis (4) (5) (6) . The. eventual severe loss of sarcoplasmic and contractile proteins in dystrophy is associated with increased activity of acidic and neutral proteinases (7) (8) (9) (10) .
The proteinase inhibitor leupeptin (11) is known to inhibit cathepsin B and calcium-activated neutral endopeptidase, proteinases thought to play an important role in muscle catabolism in dystrophy. Leupeptin and pepstatin (a similar proteinase inhibitor that acts on cathepsin D) (11, 12) , delay degeneration ofdystrophic chicken muscle in vitro and in vivo (13) (14) (15) . Likewise, normal and dystrophic mouse muscles show decreased protein degradation in vitro when incubated with leupeptin (16) .
These findings suggest that leupeptin may be able to limit proteolysis in early dystrophic lesions, minimizing muscle fiber damage. Therefore, we studied the effects of leupeptin treatment of genetically dystrophic mice.
We used C57BL/6J dy2J/dy2J mice (17, 18) , the progeny of matings between dystrophic homozygous dy2J males and brown females with transplanted ovaries from homozygous dyJ females, or of matings between the homozygous littermates that resulted from the first breeding pairs. Sixteen of the treated animals showed weakness, but a majority of the untreated animals were clinically weak. One ofus (J.H. S.) examined the histological sections with no knowledge of the treatment history of the animals. Although a spectrum of abnormalities was apparent in the dystrophic muscles, the sections could be divided into two groups: those showing no or minimal histological change and those showing evidence of a necrotizing myopathy, as defined by the presence of necrotic fibers plus at least 5% other abnormal fibers in the soleus ( Fig. 1 A and B) . These abnormal fibers 'were mainly smaller than normal, with internal nuclei. In succinate dehydrogenase preparations some fibers' that appeared normal in hematoxylin and eosin stains showed patchy or lost mitochondrial staining. Fifteen of the 16 treated animals had no significant histological changes in their muscle, whereas 19 of the 24 untreated animals' muscle sections showed a necrotizing myopathy (P < 0;001;' Table 1) .
Cross-sectional smallest diameters were measured on 200 soleus muscle fibers from each of 10 randomly selected animals, 5 treated and 5 controls. Mean fiber diameter (±SD) in the treated group was 31.5 ± 6.8 gam, and in the untreated group, 28.8 ± 10.9 m. The difference is statistically significant (P < 0.001). The muscle from untreated dystrophic animals contained many extremely small fibers as well as some hypertrophied fibers, resulting in the significantly' smaller mean fiber diameter. What is more important, 27% of the fibers had diameters outside the normal range (21-55 Mm) in untreated muscle, as opposed to 8% in treated muscle (Fig. 2) . This emphasizes the marked variability of fiber size in untreated muscle. Measurements of 300 soleus fiber diameters from two normal age-matched C57BL mice yielded a mean of35.6 ± 6.5 um, which is significantly different from the mean fiber diameter in both treated and untreated groups (P < 0.001). Leupeptin treatment therefore did not prevent some decrease in muscle fiber size, although it inhibited the clinical and histological manifestations of dystrophy.
The degree of severity of observed myopathic change varied from mild to extremely severe, and the most marked changes 7742 The publication costs ofthis article were defrayed in part by page charge payment. This article must therefore be hereby marked "advertisement" in accordance with 18 U. S. C. §1734 solely to indicate this fact. were seen in animals of all ages, indicating considerable variability in severity and rate ofprogression ofthe disease. The lack of muscle change in five control animals may have occurred because of variability in the time of onset of disease in these mice.
Ultrastructural studies of the soleus muscles of the control dystrophic animals showed marked swelling ofthe mitochondria with reduced numbers of cristae, compared to the normal appearance of electron micrographs of muscle from treated animals ( Fig. 1 E and F) .
Although swollen mitochondria are a common fixation artifact, in our samples they appeared to be characteristic of cells in the early stage of degeneration. Normal and treated muscles prepared in an identical manner did not show this change, discounting the possibility of artifact. An early effect on mitochondria in this strain ofmice has been described (18) . Succinate dehydrogenase preparations ofuntreated muscle showed fibers with absent or focally decreased staining compared with treated muscle (Fig. 1 C and D) . This finding correlates with the ultrastructural evidence of mitochondrial abnormalities. There was increased sarcoplasmic reticulum at the I band level in many fibers. Collagen was increased focally, surrounding small groups of fibers and apparently originating by formation of fibroblast processes circling individual muscle fibers.
This experiment demonstrates that leupeptin treatment of homozygous dy2J mice begun prior to the onset of weakness prevents or delays appearance of the myopathy for at least 24 weeks.
A previous study of combined leupeptin and pepstatin treatment ofdystrophic mice showed no effect (19) . The were homozygous dy mice and treatment via the subcutaneous route was begun at 35 days, at a time when the disease is well advanced in this strain. For successful treatment with a proteinase inhibitor, it may be necessary to begin before the disease process is established. The authors' suggested explanation ofthe treatment failure was that these antiproteinases are unable to enter muscle cell. However, tissue culture experiments have since suggested that these inhibitors can cross the sarcolemma to exert an antiproteolytic effect (20) . In addition, measurement of the Ca2"-activated protease activity in muscle after intraperitoneal injection of leupeptin leads to abolishment (-90%) of this activity within 24-48 hr and a return to the original after 5-6 days, again suggesting that leupeptin has entered the muscle cell (unpublished observations). Another study of the effect of intraperitoneal pepstatin on dy/dy mice, begun at 3 weeks of age, showed some beneficial effect of treatment (21) . Leupeptin inhibits cathepsin B, an enzyme increased early in human dystrophic muscle (10) that can degrade myosin. It is also a potent inhibitor ofa calcium-activated proteinase present in muscle that degrades troponin T and I as well as tropomyosin, and causes dissolution ofthe Z lines (22) (23) (24) . The results presented here indicate that increased activity ofthese and possibly other leupeptin-inhibitable proteinases play an important role in the increased muscle catabolism associated with dystrophy. They also support our previous suggestion (13, 14) of a potential therapeutic role for proteinase inhibitors in muscular dystrophy.
